Heidelberg Pharma AG
XETRA:HPHA
Intrinsic Value
Heidelberg Pharma AG is a biopharmaceutical company, which engages in the research and development of drugs for cancer patients. [ Read More ]
The intrinsic value of one
HPHA
stock under the Base Case scenario is
3.39
EUR.
Compared to the current market price of 3.03 EUR,
Heidelberg Pharma AG
is
Undervalued by 11%.
HPHA's market price has consistently been higher than its intrinsic value.This persistent overvaluation suggests the market may be overly optimistic about
HPHA or that its price is influenced by factors unrelated to fundamentals.
Heidelberg Pharma AG's market capitalization is 141.2m EUR.
HPHA stock price is 3.03 EUR.
HPHA stock price (3.03 EUR) is 11% less than its Intrinsic Value (3.39 EUR).
HPHA. Open DCF Valuation
HPHA has upside potential of 280% compared to the average analyst price target.
Open Wall St Estimates
HPHA has positive Gross Profit for the last twelve months.
HPHA's Revenue has been growing by 5% per year for the last 3 years.
HPHA's Revenue is forecast to grow at a rate of 16% per year over the next 3 years.
HPHA's Revenue has dropped by 47% over the past 12 months.
HPHA's ROE (Return on Equity) has significantly increased in the last 3 years from -217% to -35%, and is approaching profitability.
HPHA's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from -164% to -121%, and is approaching profitability.
HPHA has negative Operating Income for the last twelve months.
HPHA has negative Net Income for the last twelve months.
HPHA's ROE (Return on Equity) for the past 12 months is negative and is equal to -35%.
HPHA's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -121%.
HPHA has negative three-year average ROE (Return on Equity): -5%. The company is not efficient at transforming stockholders' equity into net income.
HPHA's short-term assets (57m EUR) exceed its short-term liabilties (20m EUR).
HPHA has negative Free Cash Flow for the last twelve months.
HPHA's long-term assets (70m EUR) exceed its long-term liabilties (21m EUR).
HPHA's D/E (Debt to Equity) is very low and is equal to 0.12.
HPHA has negative three-year average ROIC (Return on Invested Capital): -156%. The company is not efficient at using invested capital to generate operating income.
HPHA has negative Net Debt. This means that the company has more cash and short-term investments (43m EUR) than debt (6m EUR).
HPHA's Altman Z-Score is very low and is equal to -3.21.
HPHA doesn't generate enough operating income (-21m EUR) to safely cover interest payments on its debt (907k EUR).
Valuation Backtest
Heidelberg Pharma AG
Run backtest to discover the historical profit from buying and selling
HPHA
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Heidelberg Pharma AG
Balance Sheet Decomposition
Heidelberg Pharma AG
| Current Assets | 56.6m |
| Cash & Short-Term Investments | 43.4m |
| Receivables | 2.3m |
| Other Current Assets | 10.9m |
| Non-Current Assets | 13.7m |
| PP&E | 3.8m |
| Intangibles | 8.9m |
| Other Non-Current Assets | 974.8k |
| Current Liabilities | 19.8m |
| Accounts Payable | 7.9m |
| Short-Term Debt | 5.6m |
| Other Current Liabilities | 6.3m |
| Non-Current Liabilities | 1.2m |
| Long-Term Debt | 70.4k |
| Other Non-Current Liabilities | 1.2m |
Earnings Waterfall
Heidelberg Pharma AG
|
Revenue
|
9.9m
EUR
|
|
Cost of Revenue
|
-3.3m
EUR
|
|
Gross Profit
|
6.6m
EUR
|
|
Operating Expenses
|
-27.9m
EUR
|
|
Operating Income
|
-21.3m
EUR
|
|
Other Expenses
|
955.3k
EUR
|
|
Net Income
|
-20.3m
EUR
|
Free Cash Flow Analysis
Heidelberg Pharma AG
HPHA Profitability Score
Profitability Due Diligence
Heidelberg Pharma AG's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
Score
Heidelberg Pharma AG's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
HPHA Solvency Score
Solvency Due Diligence
Heidelberg Pharma AG's solvency score is 51/100. The higher the solvency score, the more solvent the company is.
Score
Heidelberg Pharma AG's solvency score is 51/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
HPHA Price Targets Summary
Heidelberg Pharma AG
According to Wall Street analysts, the average 1-year price target for
HPHA
is 11.53 EUR
with a low forecast of 11.41 EUR and a high forecast of 11.87 EUR.
Shareholder Return
HPHA Price
Heidelberg Pharma AG
| Average Annual Return | 39.3% |
| Standard Deviation of Annual Returns | 117.99% |
| Max Drawdown | -71% |
| Market Capitalization | 141.2m EUR |
| Shares Outstanding | 46 601 100 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Heidelberg Pharma AG
Country
Industry
Market Cap
Dividend Yield
Description
Heidelberg Pharma AG is a biopharmaceutical company, which engages in the research and development of drugs for cancer patients. The company is headquartered in Ladenburg, Baden-Wuerttemberg and currently employs 89 full-time employees. The company went IPO on 2006-11-13. The firm focuses on the research and development of therapy treatments for oncology area. The company aims at applying toxin Amanitin into cancer therapies using its Antibody Targeted Amanitin Conjugate (ATAC) technology. The Company’s pipeline includes a number of drug candidates, such as HDP-101, a B-cell maturation antigen ATAC for multiple myeloma; PSMA-ATAC, prostate-specific membrane antigens, and CD19-ATAC, a B-lymphocyte antigen. Through partnerships, the Company develops clinical assets, including MESUPRON, REDECTANE and RENCAREX. The company also offers preclinical contract research services.
Contact
IPO
Employees
Officers
The intrinsic value of one
HPHA
stock under the Base Case scenario is
3.39
EUR.
Compared to the current market price of 3.03 EUR,
Heidelberg Pharma AG
is
Undervalued by 11%.
You don't have any saved screeners yet
